An interdisciplinary team at Harvard’s Wyss Institute employed AI-enabled physics-based molecular modeling combined with molecular dynamics to repurpose and optimize FDA-approved drugs, identifying bemcentinib as a promising oral antiviral against multiple respiratory coronaviruses. Subsequent chemical optimization yielded a broad-spectrum candidate with enhanced efficacy, addressing the urgent need for accessible treatments amid emerging coronavirus variants.